No one offered a cent for tt-034. This time a nasdaq entity owned by a specialist parent company has paid 10 mil US up front and committed to milestone payments of 200 mil. Also OPMD was a cover story in Nature Magazine, has been given orphan designation in the USA and Europe plus world-class scientists at Axovant are hitching their names to it. David Suhy described it as a home run.
March 29 - follow the money, page-17
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
